ABAnita J. Bechtholt-Gompf

Anita J. Bechtholt-Gompf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anita J. Bechtholt-Gompf has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Dost Öngür

    Department of Psychiatry, Harvard Medical School—McLean Hospital, Belmont, USA

    6 shared publications
  • Bruce M Cohen

    Department of Psychiatry, Harvard Medical School—McLean Hospital, Belmont, USA

    3 shared publications
  • Bruce M. Cohen

    Department of Psychiatry Harvard Medical School McLean Hospital Belmont MA USA

    3 shared publications
  • Karen L. Smith

    Department of Psychiatry Harvard Medical School McLean Hospital Belmont MA USA

    3 shared publications
  • William A Carlezon

    Department of Psychiatry, Harvard Medical School—McLean Hospital, Belmont, USA

    3 shared publications
  • Ashlee Van'T Veer

    Department of Psychiatry Harvard Medical School McLean Hospital Belmont MA USA; National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda MD USA

    2 shared publications

Latest Publications

  • Open Access

    Kappa‐opioid receptors differentially regulate low and high levels of ethanol intake in female mice

    by Ashlee Van'T Veer, Karen L. Smith, Bruce M. Cohen, William A. Carlezon, Anita J. Bechtholt

    Introduction: Studies in laboratory animals and humans indicate that endogenous opioids play an important role in regulating the rewarding value of various drugs, including ethanol (EtOH). Indeed, opioid antagonists are currently a front‐line treatment for alcoholism in humans. Although roles for mu‐ and delta‐opioid receptors have been characterized, the contribution of kappa‐opioid receptors (KORs) is less clear. There is evidence that changes inKORsystem function can decrease or increase EtOHdrinking, depending on test conditions. For example, female mice lacking preprodynorphin – the precursor to the endogenousKORligand dynorphin – have reduced EtOHintake. Considering thatKORs can regulate dopamine (DA) transmission, we hypothesized thatKORs expressed onDAneurons would play a prominent role in EtOHintake in females.Methods: We used a Cre/loxPrecombination strategy to ablateKORs throughout the body or specifically on dopamine uptake transporter (DAT)‐expressing neurons to investigate the role ofKORs on preference for and intake of EtOH (2‐bottle choice), the transition from moderate to excessive EtOH drinking (intermittent EtOH access), and binge EtOH drinking (drinking in the dark [DID]).Results: KORdeletion decreased preference for EtOH, although this effect was less pronounced when EtOHintake increased beyond relatively low levels.Discussion: Our findings indicate thatKORactivation increases EtOHdrinking via effects mediated, at least in part, byKORs onDAneurons. While the mechanisms of this regulation remain unknown, previous work suggests that alterations in negative reinforcement processes or sensitivity to the sensory properties of EtOHcan affect preference and intake.


  • Open Access

    Blockade of the GLT-1 Transporter in the Central Nucleus of the Amygdala Induces both Anxiety and Depressive-Like Symptoms

    by Catherine S John, Elizabeth I Sypek, William A Carlezon, Bruce M Cohen, Dost Öngür, Anita J Bechtholt

    Depression has been associated with abnormalities in glutamatergic neurotransmission and decreased astrocyte number in limbic areas. We previously demonstrated that global and prefrontal cortical blockade of the astrocytic glutamate transporter (GLT-1) induces anhedonia and c-Fos expression in areas that regulate anxiety, including the central amygdala (CEA). Given the role of the amygdala in anxiety and the high degree of comorbidity between anxiety and depression, we hypothesized that GLT-1 blockade in the CEA would induce symptoms of anhedonia and anxiety in rats. We microinjected the GLT-1 inhibitor, dihydrokainic acid (DHK), into the CEA and examined effects on intracranial self-stimulation (ICSS) as an index of hedonic state, and on behavior in two anxiety paradigms, elevated plus maze (EPM) and fear conditioning. At lower doses, intra-CEA DHK produced modest increases in ICSS responding (T0). Higher doses resulted in complete cessation of responding for 15 min, suggesting an anhedonic or depressive-like effect. Intra-CEA DHK also increased anxiety-like behavior such that percent time in the open arms and total entries were decreased in the EPM and acquisition of freezing behavior to the tone was increased in a fear-conditioning paradigm. These effects did not appear to be explained by non-specific changes in activity, because effects on fear conditioning were assessed in a drug-free state, and a separate activity test showed no significant effects of intra-CEA DHK on locomotion. Taken together, these studies suggest that blockade of GLT-1 in the CEA is sufficient to induce both anhedonia and anxiety and therefore that a lack of glutamate uptake resulting from glial deficits may contribute to the comorbidity of depression and anxiety.


  • Exploring the Role of Central Astrocytic Glutamate Uptake in Ethanol Reward in Mice

    by Karen L. Smith, Catherine S. John, Elizabeth I. Sypek, Dost Öngür, Bruce M. Cohen, Sarah M. Barry, Anita J. Bechtholt

    Background: Alcoholism is associated with specific brain abnormalities revealed through postmortem studies, including a reduction in glial cell number and dysregulated glutamatergic neurotransmission. Whether these abnormalities contribute to the etiology of alcoholism, are consequences of alcohol use, or both is still unknown.Methods: We investigated the role of astrocytic glutamate uptake in ethanol (EtOH) binge drinking in mice, using the “drinking in the dark” (DID) paradigm by blocking the astrocytic glutamate transporter (GLT‐1) with intracerebroventricular (ICV) administration of dihydrokainic acid (DHK). To determine whether astrocytic glutamate uptake regulates the conditioned rewarding effects of EtOH, we examined the effects ofICV DHKon the acquisition and expression of EtOH‐induced conditioned place preference.Results: Blocking central astrocytic glutamate uptake selectively attenuated EtOHbinge drinking behavior in mice.DHKdid not alter the acquisition or expression of preference for EtOH‐associated cues, indicating that reduced astrocytic glutamate trafficking may decrease binge‐like drinking without altering the conditioned rewarding effects of EtOH.Conclusions: Several alternative conclusions are plausible, however, interpreting these data in the context of the human literature, these findings suggest that the reduction of glia in the alcoholic brain may not be a predisposing factor to developing alcoholism and could be a consequence of EtOHtoxicity that decreases excessive EtOHintake.


  • Blockade of Astrocytic Glutamate Uptake in the Prefrontal Cortex Induces Anhedonia

    by Catherine S John, Karen L Smith, Ashlee Van'T Veer, Heinrich S Gompf, William A Carlezon, Bruce M Cohen, Dost Öngür, Anita J Bechtholt-Gompf

    Major depression is associated with both dysregulated glutamatergic neurotransmission and fewer astrocytes in limbic areas including the prefrontal cortex (PFC). These deficits may be functionally related. Notably, astrocytes regulate glutamate levels by removing glutamate from the synapse via the glutamate transporter (GLT-1). Previously, we demonstrated that central blockade of GLT-1 induces anhedonia and c-Fos expression in the PFC. Given the role of the PFC in regulating mood, we hypothesized that GLT-1 blockade in the PFC alone would be sufficient to induce anhedonia in rats. We microinjected the GLT-1 inhibitor, dihydrokainic acid (DHK), into the PFC and examined the effects on mood using intracranial self-stimulation (ICSS). At lower doses, intra-PFC DHK produced modest increases in ICSS thresholds, reflecting a depressive-like effect. At higher doses, intra-PFC DHK resulted in cessation of responding. We conducted further tests to clarify whether this total cessation of responding was related to an anhedonic state (tested by sucrose intake), a nonspecific result of motor impairment (measured by the tape test), or seizure activity (measured with electroencephalogram (EEG)). The highest dose of DHK increased latency to begin drinking without altering total sucrose intake. Furthermore, neither motor impairment nor evidence of seizure activity was observed in the tape test or EEG recordings. A decrease in reward value followed by complete cessation of ICSS responding suggests an anhedonic-like effect of intra-PFC DHK; a conclusion that was substantiated by an increased latency to begin sucrose drinking. Overall, these results suggest that blockade of astrocytic glutamate uptake in the PFC is sufficient to produce anhedonia, a core symptom of depression.


  • Re: concerns about the antidepressant-like effects of high-dose ketamine in mice

    by Anita Bechtholt-Gompf, Karen Smith, Catherine John, Hannah Kang, William Carlezon, Bruce Cohen, Dost Öngür


  • CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy

    by Anita J. Bechtholt-Gompf, Karen L. Smith, Catherine S. John, Hannah H. Kang, William A. Carlezon, Bruce M. Cohen, Dost Öngür

    In patients, ketamine is a fast-acting antidepressant that can induce long-lasting symptom relief. Similar rapid effects have been reported in rodents, but reports of lasting effects are limited.


  • Blockade of Astrocytic Glutamate Uptake in Rats Induces Signs of Anhedonia and Impaired Spatial Memory

    by Anita J Bechtholt-Gompf, Hali V Walther, Martha A Adams, William A Carlezon, Dost Öngür, Bruce M Cohen

    Mood disorders are associated with regional brain abnormalities, including reductions in glial cell and neuron number, glutamatergic irregularities, and differential patterns of brain activation. Because astrocytes are modulators of neuronal activity and are important in trafficking the excitatory neurotransmitter glutamate, it is possible that these pathologies are interrelated and contribute to some of the behavioral signs that characterize depression and related disorders. We tested this hypothesis by determining whether depressive-like signs were induced by blocking central astrocytic glutamate uptake with the astrocytic glutamate transporter (GLT-1) inhibitor, dihydrokainic acid (DHK), in behavioral tests that quantify aspects of mood, including reward and euthymia/dysthymia: intracranial self-stimulation (ICSS) and place conditioning. We found that DHK elevated ICSS thresholds, a depressive-like effect that could reflect reduced sensitivity to reward (anhedonia) or increased aversion (dysphoria). However, DHK treatment did not establish conditioned place aversions, suggesting that this treatment does not induce dysphoria. To identify the brain regions mediating the behavioral effects of DHK, we examined c-Fos expression in areas implicated in motivation and emotion. DHK increased c-Fos expression in many of these regions. The dentate gyrus of the hippocampus was robustly activated, which led us to explore whether DHK alters hippocampal learning. DHK impaired spatial memory in the MWM. These findings identify disruption of astrocyte glutamate uptake as one component of the complex circuits that mediate anhedonia and cognitive impairment, both of which are common symptoms of depression. These finding may have implications for the etiology of depression and other disorders that share the features of anhedonia and cognitive impairment.